New combo therapy aims to keep advanced breast cancer in check longer
NCT ID NCT07179939
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether a maintenance therapy of trastuzumab plus either pyrotinib or dalpiciclib and endocrine therapy can delay disease progression in people with HER2-positive advanced breast cancer. After an initial treatment with trastuzumab rezetecan, 288 participants will receive one of the maintenance combinations based on their hormone receptor status. The study aims to see if this approach improves how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab rezetecan (SHR-A1811), pyrotinib, dalpiciclib, trastuzumab, and endocrine therapy (letrozole, anastrozole, exemestane, fulvestrant, leuprorelin, or goserelin)
- What this could lead to
- If successful, this could point toward a more effective maintenance strategy to delay disease progression in people with HER2-positive advanced breast cancer.
- What could go wrong
- This is an early phase II trial, so results are not yet proven. The combination may cause side effects or not improve outcomes compared to existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?